Equities researchers at Stifel Nicolaus began coverage on shares of Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) in a research report issued on Friday, Briefing.com reports. The brokerage set a “buy” rating and a $49.00 price target on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 88.46% from the stock’s current price.
ORKA has been the topic of several other reports. HC Wainwright assumed coverage on shares of Oruka Therapeutics in a research report on Monday. They issued a “buy” rating and a $45.00 price target on the stock. Lifesci Capital assumed coverage on shares of Oruka Therapeutics in a research report on Monday, September 16th. They issued an “outperform” rating and a $41.00 price target on the stock. Jefferies Financial Group began coverage on shares of Oruka Therapeutics in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price target on the stock. Wedbush began coverage on shares of Oruka Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 price objective for the company. Finally, TD Cowen began coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They set a “buy” rating for the company. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Oruka Therapeutics currently has a consensus rating of “Buy” and an average target price of $43.17.
Check Out Our Latest Research Report on ORKA
Oruka Therapeutics Trading Down 8.6 %
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($25.92) earnings per share (EPS) for the quarter. Research analysts forecast that Oruka Therapeutics will post -1.62 EPS for the current year.
About Oruka Therapeutics
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.
Featured Stories
- Five stocks we like better than Oruka Therapeutics
- Dividend Payout Ratio Calculator
- S&P 500 Hits Record Highs: 3 Stocks With Huge Growth Potential
- Upcoming IPO Stock Lockup Period, Explained
- AbbVie Stock Eyes New Highs: Analysts See Strong Growth Potential
- Using the MarketBeat Dividend Tax Calculator
- AZZ Stock Gains Momentum: Analysts Forecast 25% Upside From Here
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.